PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 65 filers reported holding PROTAGONIST THERAPEUTICS INC in Q1 2019. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,185 | -39.6% | 131 | 0.0% | 0.00% | -50.0% |
| Q2 2023 | $3,618 | +20.1% | 131 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $3,013 | -20.0% | 131 | -62.0% | 0.00% | 0.0% |
| Q4 2022 | $3,764 | +25.5% | 345 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $3,000 | 0.0% | 345 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $3,000 | -66.7% | 345 | +38.0% | 0.00% | -60.0% |
| Q4 2021 | $9,000 | +125.0% | 250 | 0.0% | 0.01% | +150.0% |
| Q3 2021 | $4,000 | -63.6% | 250 | 0.0% | 0.00% | -66.7% |
| Q2 2021 | $11,000 | +83.3% | 250 | 0.0% | 0.01% | +100.0% |
| Q1 2021 | $6,000 | +200.0% | 250 | +110.1% | 0.00% | +200.0% |
| Q4 2020 | $2,000 | 0.0% | 119 | 0.0% | 0.00% | -50.0% |
| Q2 2020 | $2,000 | +100.0% | 119 | 0.0% | 0.00% | +100.0% |
| Q3 2019 | $1,000 | 0.0% | 119 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $1,000 | 0.0% | 119 | 0.0% | 0.00% | 0.0% |
| Q1 2019 | $1,000 | -66.7% | 119 | -52.8% | 0.00% | 0.0% |
| Q3 2018 | $3,000 | – | 252 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Pharmstandard International S.A. | 750,632 | $7,724,000 | 26.59% |
| BVF INC/IL | 2,617,967 | $26,939,000 | 2.37% |
| GREAT POINT PARTNERS LLC | 982,449 | $10,109,000 | 1.58% |
| Alambic Investment Management, L.P. | 65,128 | $670,000 | 0.53% |
| FARALLON CAPITAL MANAGEMENT LLC | 2,243,202 | $23,083,000 | 0.14% |
| ALGERT GLOBAL LLC | 44,477 | $458,000 | 0.10% |
| Monashee Investment Management LLC | 42,945 | $442,000 | 0.09% |
| Tekla Capital Management LLC | 219,042 | $2,254,000 | 0.08% |
| Spark Investment Management LLC | 138,800 | $1,428,000 | 0.08% |
| OXFORD ASSET MANAGEMENT LLP | 187,653 | $1,904,000 | 0.04% |